Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ: AUPH )

7.900 +0.170 (+2.20%)
Streaming Delayed Price Updated: 1:27 PM EST, Jan 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 447,872
Open 7.690
Bid (Size) 7.900 (16)
Ask (Size) 7.910 (9)
Prev. Close 7.730
Today's Range 7.665 - 7.910
52wk Range 4.710 - 10.67
Shares Outstanding 128,395,927
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
-9.92%
-9.92%
1 Month
-11.73%
-11.73%
3 Month
+13.02%
+13.02%
6 Month
+42.09%
+42.09%
1 Year
-1.86%
-1.86%

More News

Read More
Aurinia to Participate in Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Board Restructuring
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2024 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Provides Update on Proxy Statement
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.